Published on 04/12/2025
Understanding Warning Letters: Structure/Function Claims vs Disease Claims in Dietary Supplements
The regulation of dietary supplements in the United States is governed primarily by the Food and Drug Administration (FDA) under the Dietary Supplement Health and Education Act (DSHEA). The importance of adhering to FDA regulations cannot be overstated, particularly when it comes to the distinction between structure/function claims and disease claims. This article will explore case studies of FDA warning letters pertaining to non-compliant supplement claims, offering regulatory and compliance professionals crucial insights into labeling rules, claim substantiation, and marketing review processes.
Introduction to FDA Claim Rules for Dietary Supplements
Understanding FDA regulations around dietary supplements is essential for compliance professionals within the industry. Under 21 CFR Part 101, dietary supplements can feature structure/function claims, which describe the role of a nutrient or dietary ingredient intended to affect the structure or function of the body, or disease claims, which assert that a product can treat or prevent a specific
Structure/function claims are permitted under the current regulations, provided they are truthful and not misleading. On the other hand, disease claims are prohibited unless the product is approved as a drug by the FDA. This distinction is critical, as mislabeling or misrepresenting products can lead to significant regulatory repercussions, including warning letters.
Case Study Analysis: Warning Letters on Non-Compliant Claims
Throughout recent years, the FDA has issued numerous warning letters to companies that have made non-compliant claims regarding their dietary supplements. These letters serve as both a notification of regulatory violations and a guidance tool to help companies rectify their promotional practices. Below we analyze specific case studies focusing on the distinction between structure/function claims vs disease claims.
Case Study 1: XYZ Supplements
In a recent warning letter, XYZ Supplements claimed that their product, “Boost Immune Defense,” was intended to “prevent the flu and other illnesses.” This statement was classified as a disease claim because it suggested a preventative effect on specific diseases, which falls outside the permissible claims for dietary supplements.
The FDA highlighted that this kind of assertion requires strong clinical evidence to substantiate it as a drug claim, not merely as a dietary supplement. As a result, XYZ Supplements was directed to remove the misleading claims from their marketing materials and establish appropriate structure/function claims instead. Failure to comply could result in further enforcement actions.
Case Study 2: ABC Wellness
ABC Wellness faced a similar situation where their product, “Joint Relief,” stated that it was “clinically shown to reduce arthritis symptoms.” This assertion was deemed a disease claim under FDA regulations. The company received a warning letter indicating that claims must be based on scientific evidence that includes adequate substantiation reflecting the product’s intended use.
In this scenario, ABC Wellness was instructed to conduct a marketing review to realign their claims with FDA guidelines. This included referencing appropriate studies to back any structure/function claims they wished to make regarding the product.
Understanding Structure/Function Claims
Structure/function claims must be truthful and not misleading. The claims may describe how a nutrient or dietary supplement affects the structure/function of the human body. Examples include statements such as “calcium builds strong bones” or “fiber maintains bowel health.” These claims do not imply that the product can diagnose, prevent, mitigate, or treat any disease.
According to 21 CFR 101.93, if a company opts to make a structure/function claim, it is required to notify the FDA within 30 days after the first marketing of the product with such claims. This notification must include the statement made and its intended use.
Consequences of Non-Compliance
The potential consequences of failing to comply with FDA regulations regarding claims are significant. Warning letters are often the first line of action taken by the FDA to address violations. The letters inform companies of the nature of the violation, expectations for corrective action, and potentially, timelines for compliance.
In addition to receiving a warning letter, companies may face penalties that include fines, product seizures, and restrictions on marketing. Non-compliance can lead to a tarnished reputation, diminished trust among consumers, and reduced sales. It is crucial for organizations to establish robust compliance strategies to mitigate these risks.
Claim Substantiation: Best Practices for Compliance
Substantiation of claims made on dietary supplements is both a regulatory requirement and a critical component for maintaining consumer trust. To ensure compliance, companies should implement best practices in their marketing and research efforts.
- Scientific Evidence: Ensure that all claims are thoroughly backed by scientific research. Utilize clinical studies, peer-reviewed articles, and other reputable sources.
- Clear Documentation: Maintain detailed records that support your claims, including the methodologies used in studies and the specific results obtained.
- Legal Review: Conduct regular legal analyses of labeling and promotional materials to ensure compliance with FDA claim rules.
- Staff Training: Provide ongoing training for marketing and regulatory teams about FDA guidelines and the importance of compliance in preventing violations.
Marketing Review Processes
Establishing a thorough marketing review process is essential to avoid potential pitfalls in making claims. A well-structured review process should include the following steps:
- Initial Draft Review: Assess the proposed claims against FDA guidelines during the early stages of marketing material development.
- Legal Compliance Check: Involve legal counsel to identify any potential regulatory issues with claims and labeling.
- Peer Review: Employ internal or external experts to evaluate the scientific substantiation supporting the claims.
- Final Approval: Obtain approval from all relevant stakeholders before publishing promotional materials.
Strategies for Effective Compliance in Dietary Supplement Labeling
To navigate the complexities of dietary supplement labeling and ensure compliance with FDA regulations, companies can adopt several strategic approaches:
- Implement Comprehensive Written Policies: Develop and maintain written policies outlining your compliance strategy for label claims, including feedback on structure/function claims versus disease claims.
- Continuous Education: Keep regulatory teams updated on evolving FDA guidelines, including changes in claim regulations.
- Engage Third-Party Consultants: When necessary, enlist the help of third-party consulting firms specializing in regulatory compliance to supplement internal capabilities.
Conclusion
The delineation between structure/function claims and disease claims is a critical consideration for compliance in dietary supplements. Case studies of warning letters serve as cautionary tales for industry players, underscoring the importance of vigilance in claim substantiation and adherence to FDA claim rules. By instituting best practices and fostering a culture of compliance within your organization, you can safeguard against regulatory violations and enhance consumer trust in your products.
For further information on FDA regulations concerning dietary supplements, industry professionals may refer to the relevant sections of the FDA’s labeling guidelines or the FDA’s guidance on claim substantiation.